Yüklüyor......
Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
Constitutively active mutated BRAF kinase occurs in more than 40% of patients suffering from melanoma. To block its activity, a specific inhibitor, vemurafenib, is applied as a therapy. Unfortunately, patients develop resistance to this drug rather quickly. Previously, we demonstrated that pairs of...
Kaydedildi:
| Yayımlandı: | Int J Mol Sci |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6981576/ https://ncbi.nlm.nih.gov/pubmed/31877948 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21010113 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|